Raymond James maintains Outperform rating on Regeneron with $911 target
October 8, 2026 5:20 AM
Raymond James analyst Chris Raymond reiterated an Outperform rating and a $911.00 price target on Regeneron Pharmaceuticals (NASDAQ: REGN).Raymond noted ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
